Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Authors:
Preprint
Abstract
Vaccines and drugs have helped reduce disease severity and blunt the spread of SARS-CoV-2. However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susceptibility of natural variants of the main protease (M pro /3CL pro ) of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in M pro confer resistance to nirmatrelvir (the active component of Paxlovid). An additional clinical-stage inhibitor, ensitrelvir (Xocova), shows a different resistance mutation profile. Importantly, phylogenetic analyses indicate that several of these resistant variants have pre-existed the introduction of these drugs into the human population and are capable of spreading. These results encourage the monitoring of resistance variants and the development of additional protease inhibitors and other antiviral drugs with different mechanisms of action and resistance profiles for combinatorial therapy. One Sentence Summary: Resistance to protease inhibitor drugs, nirmatrelvir (Paxlovid) and ensitrelvir (Xocova), exists in SARS-CoV-2 variants in the human population.Keywords
All Related Versions
- Published version: Science Advances, 9 (13), 538.
This publication has 55 references indexed in Scilit:
- MDAnalysis: A toolkit for the analysis of molecular dynamics simulationsJournal of Computational Chemistry, 2011
- PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKaPredictionsJournal of Chemical Theory and Computation, 2011
- Long-Range Cooperative Interactions Modulate Dimerization in SARS 3CLproBiochemistry, 2006
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- Combating Susceptibility to Drug ResistanceChemistry & Biology, 2004
- Characterization of SARS main protease and inhibitor assay using a fluorogenic substrateBiochemical and Biophysical Research Communications, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Comparison of simple potential functions for simulating liquid waterThe Journal of Chemical Physics, 1983